Human PD-L2/B7-DC Protein
Catalog No: PDL2-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human PD-L2/B7-DC Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Leu20-Thr220 (UniProt accession: Q9BQ51).
Product Details
- Molecular Aliases
- PDL2; PD-L2; Butyrophilin B7-DC; CD273, PDCD1 ligand 2; PDCD1L2; PDCD1LG2; B7DC; bA574F11.2; Btdc;Butyrophilin B7DC
- Protein Length
- Leu20-Thr220
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 48.60 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human PD-L2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human PD-L2 is greater than 95% as determined by SEC-HPLC.
Loaded Human PD-L2, hFc Tag on ProA-Biosensor can bind Human PD-1, His Tag with an affinity constant of 1.17 µM as determined in BLI assay. (QC Test)
Human PD-L2, hFc Tag captured on CM5 Chip via Protein A can bind Human PD-1, His Tag with an affinity constant of 0.21 μM as determined in SPR assay (Biacore T200).
Background
PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4 T cells. At low antigen concentrations, PD-L2-PD-1 interactions inhibit strong B7-CD28 signals.
References
- Yearley JH, Gibson C, Yu N, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017;23(12):3158-3167. doi:10.1158/1078-0432.CCR-16-1761 Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.